262
views
0
recommends
+1 Recommend
0 collections
    24
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

      research-article
      1 , 2 , 3 , 4 , 3 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 2 , 1 , 2 , 1 , 3 , 1 , 2 , 1 , 1 , 1 , 2 , 5 , 1 , 1 , 1 , 2 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 3 , 3 , 3 , 3 , 3 , 6 , 3 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 7 , 7 , 7 , 8 , 1 , 2 , 7 , 9 , 1 , 2 , 3 , 4 , 1 , 2 , 4 , 1 , 2 , 4
      Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumor progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumor, a brain metastasis, and a xenograft derived from the primary tumor. The metastasis contained two de novo mutations and a large deletion not present in the primary tumor, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumor mutations, and displayed a mutation enrichment pattern that paralleled the metastasis (16 of 20 genes). Two overlapping large deletions, encompassing CTNNA1, were present in all three tumor samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared to the primary tumor suggest that secondary tumors may arise from a minority of cells within the primary.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          The genomic landscapes of human breast and colorectal cancers.

          Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalog the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene "mountains" and a much larger number of gene "hills" that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

            FBW7 (F-box and WD repeat domain-containing 7) is the substrate recognition component of an evolutionary conserved SCF (complex of SKP1, CUL1 and F-box protein)-type ubiquitin ligase. SCF(FBW7) degrades several proto-oncogenes that function in cellular growth and division pathways, including MYC, cyclin E, Notch and JUN. FBW7 is also a tumour suppressor, the regulatory network of which is perturbed in many human malignancies. Numerous cancer-associated mutations in FBW7 and its substrates have been identified, and loss of FBW7 function causes chromosomal instability and tumorigenesis. This Review focuses on structural and functional aspects of FBW7 and its role in the development of cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

              Lay Summary Acute myeloid leukemia is a highly malignant hematopoietic tumor that affects about 13,000 adults yearly in the United States. The treatment of this disease has changed little in the past two decades, since most of the genetic events that initiate the disease remain undiscovered. Whole genome sequencing is now possible at a reasonable cost and timeframe to utilize this approach for unbiased discovery of tumor-specific somatic mutations that alter the protein-coding genes. Here we show the results obtained by sequencing a typical acute myeloid leukemia genome and its matched normal counterpart, obtained from the patient’s skin. We discovered 10 genes with acquired mutations; two were previously described mutations thought to contribute to tumor progression, and 8 were novel mutations present in virtually all tumor cells at presentation and relapse, whose function is not yet known. Our study establishes whole genome sequencing as an unbiased method for discovering initiating mutations in cancer genomes, and for identifying novel genes that may respond to targeted therapies. We used massively parallel sequencing technology to sequence the genomic DNA of tumor and normal skin cells obtained from a patient with a typical presentation of FAB M1 Acute Myeloid Leukemia (AML) with normal cytogenetics. 32.7-fold ‘haploid’ coverage (98 billion bases) was obtained for the tumor genome, and 13.9-fold coverage (41.8 billion bases) was obtained for the normal sample. Of 2,647,695 well-supported Single Nucleotide Variants (SNVs) found in the tumor genome, 2,588,486 (97.7%) also were detected in the patient’s skin genome, limiting the number of variants that required further study. For the purposes of this initial study, we restricted our downstream analysis to the coding sequences of annotated genes: we found only eight heterozygous, non-synonymous somatic SNVs in the entire genome. All were novel, including mutations in protocadherin/cadherin family members (CDH24 and PCLKC), G-protein coupled receptors (GPR123 and EBI2), a protein phosphatase (PTPRT), a potential guanine nucleotide exchange factor (KNDC1), a peptide/drug transporter (SLC15A1), and a glutamate receptor gene (GRINL1B). We also detected previously described, recurrent somatic insertions in the FLT3 and NPM1 genes. Based on deep readcount data, we determined that all of these mutations (except FLT3) were present in nearly all tumor cells at presentation, and again at relapse 11 months later, suggesting that the patient had a single dominant clone containing all of the mutations. These results demonstrate the power of whole genome sequencing to discover novel cancer-associated mutations.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                0028-0836
                1476-4687
                24 March 2010
                15 April 2010
                15 October 2010
                : 464
                : 7291
                : 999-1005
                Affiliations
                [1 ]The Genome Center at Washington University, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [2 ]Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [3 ]Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [4 ]Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [5 ]Division of Statistical Genomics, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [6 ]Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [7 ]Department of Surgery and the Young Women's Breast Cancer Program, Washington University School of Medicine, St Louis, Missouri 63108, USA
                [8 ]Department of Genetics, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
                [9 ]Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63108, USA
                Author notes
                [** ]Correspondence to Richard K. Wilson ( rwilson@ 123456wustl.edu )
                [*]

                These authors contributed equally to this work

                Article
                nihpa187230
                10.1038/nature08989
                2872544
                20393555
                e990993e-bdd1-45fb-9cb1-c661b50aea05

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Human Genome Research Institute : NHGRI
                Award ID: U54 HG003079-07 ||HG
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article